

***Clear-Cut Medical announces CE Marking of its ClearSight™
MRI system for the examination of breast tissue***

Rehovot, Israel, September 23, 2014 – Clear-Cut Medical announced the CE Marking of its ClearSight™ MRI system for the examination of breast tissue.

The ClearSight™ system is a revolutionary compact Magnetic Resonance Imaging system intended for the assessment of the margins of excised breast lumps taken from breast cancer patients undergoing Breast Conserving Surgery or Lumpectomy procedures. The CE Marking of the ClearSight™ system allows the commercialization of the system in Europe.

"This is a major milestone both for our company and for patients undergoing Breast Conserving Surgery" stated Eyal Kolka, Clear-Cut's CEO, "MRI is well recognized as the modality of choice for breast imaging, but due to its size and cost it was practically not accessible in real time for assisting surgical procedures. Currently as high as 30% of breast cancer patients undergoing lumpectomy return for a re-do operation due to 'positive margin' analyzed by a pathologist within one week or more. Now, our ClearSight™ system brings the power of MRI into the operating room aiming to assist the breast surgeon in improving the quality of care".

About Clear-Cut Medical

Clear-Cut Medical was established in 2010 to develop and commercialize its proprietary MRI technology for real-time assessment of excised tissue. The company's first product, the ClearSight™ system, is intended for intraoperative margin assessment of surgically removed lumps in Breast Conserving Surgery.

Contact:

Eyal Kolka
CEO
+972-8-6326004
eyal@clrcut.com
www.clrcut.com